Does Reactive Urothelial Cells Mean Cancer?

Reactive urothelial cells on a urine cytology report do not mean cancer. They are cells from the lining of the urinary tract that look slightly abnormal under a microscope because something has irritated or inflamed them. Infections, kidney stones, catheters, and even recent medical procedures can all cause these changes. The word “reactive” is specifically chosen by pathologists to signal that the cells are responding to an irritant rather than growing out of control, but the finding can still feel alarming when you see it on a lab report.

What Reactive Urothelial Cells Look Like Under the Microscope

The urinary tract is lined with a specialized tissue called urothelium. When that tissue gets irritated, the cells shed into urine can show enlarged nuclei, a slightly different shape, or small internal changes that catch a pathologist’s eye. The key detail that separates these reactive cells from cancerous ones is proportion: in a reactive cell, the nucleus may be bigger than usual but still takes up less than half the cell’s total area. That ratio matters because cancer cells tend to have nuclei that crowd out the surrounding cytoplasm.

Pathologists also look at the overall background of the urine sample. Reactive specimens tend to show a mix of inflammatory cells, a range of small and large urothelial cells, loose flat clusters, and sometimes cells with visible vacuoles in their cytoplasm. These features together paint a picture of irritation rather than malignancy. By contrast, cancer cells show a more monotonous population of abnormal-looking cells with darker nuclei, irregular borders, and a higher nucleus-to-cytoplasm ratio.

Common Reasons Urothelial Cells Become Reactive

The most frequent trigger is a urinary tract infection. Bacteria inflame the bladder lining, and the cells that slough off during that inflammation look noticeably different from cells shed by a healthy bladder. Once the infection clears, a repeat urine cytology sample typically returns to normal.

Kidney stones are another common culprit. Stones scrape and irritate the urothelium as they move through the urinary tract, and the resulting cellular changes can look suspicious enough to prompt follow-up. One study found that among patients whose urine samples contained unusual-looking tissue fragments, nearly a third were eventually diagnosed with kidney stones rather than any malignancy.¹ Patients with stones also showed more red blood cells, white blood cells, and nuclear changes in their urine compared to stone-free controls.²

Instrumentation plays a role too. Catheters, cystoscopes, and other devices physically disturb the bladder lining. Even a single catheterization can shed cells that look mildly atypical under a microscope. This is one reason pathologists note whether a urine specimen was voided naturally or collected after a procedure.

When Treatment Itself Makes Cells Look Suspicious

If you have already been treated for bladder cancer, the treatments meant to eliminate it can ironically make follow-up urine samples harder to read. Chemotherapy drugs instilled directly into the bladder, BCG immunotherapy, radiation, and even newer approaches like photodynamic therapy all alter the urothelial lining in ways that can mimic carcinoma in situ or even invasive cancer under the microscope.³

Among the worst offenders is mitomycin C, a drug sometimes used right after a bladder tumor is surgically removed to reduce recurrence. The cellular changes it produces can closely resemble urothelial dysplasia or carcinoma in situ. BCG immunotherapy and platinum-based chemotherapy cause similar confusion.⁴ For pathologists, knowing a patient’s treatment history is essential. Without that context, therapy-related atypia can easily be misread as recurrent disease.

Viral Infections That Mimic Cancer Cells

BK virus deserves special mention. This common virus reactivates in people with weakened immune systems, particularly kidney transplant recipients who take immunosuppressive drugs. When BK virus infects urothelial cells, it produces what pathologists call “decoy cells,” which can look strikingly similar to high-grade urothelial carcinoma. The enlarged, darkened nuclei of decoy cells have fooled even experienced microscopists, and the consequences of a false cancer diagnosis in a transplant patient are serious.⁵ Specialized staining and awareness of the patient’s transplant status help pathologists avoid that trap, though the situation is complicated by the fact that a transplant recipient can have both BK virus and a genuine bladder tumor at the same time.

The Atypical Category and Why It Creates Anxiety

Not every urine cytology result falls neatly into “reactive” or “malignant.” There is a middle ground called “atypical urothelial cells,” and this is the category that generates the most worry. The Paris System for Reporting Urinary Cytology, a standardized framework adopted widely by pathology labs, was designed in part to tighten definitions and reduce the number of cases dumped into this ambiguous bin.⁶

The difficulty is real. One of the most common diagnostic challenges in urine cytology is telling high-grade cancer apart from benign look-alikes, especially when the sample has been sitting in urine for a long time, when there is background inflammation, or when a recent procedure has disturbed the tissue. Low-grade tumors add another layer of complexity: they shed cells infrequently in voided urine and can look nearly identical to reactive cells.⁷ So a result that says “atypical” is not the same as a result that says “reactive,” and it warrants closer follow-up, but it still does not equal a cancer diagnosis.

How Pathologists Formally Distinguish Reactive From Cancerous

The distinction between reactive urothelial proliferation and low-grade urothelial carcinoma comes down to a handful of microscopic features. A study that ran statistical modeling on cytology samples identified four features with the strongest discriminating power: an increased number of monotonous single cells (not the large umbrella-shaped cells you normally see), a high nucleus-to-cytoplasm ratio, hyperchromasia (darker-than-normal nuclei), and the absence of a normal mix of small and large urothelial cells.⁸

Reactive samples, by contrast, tend to show features that point away from cancer: an inflammatory background, a mixture of cell sizes, loose flat sheets of cells, and cytoplasm with visible vacuoles. When a pathologist sees that constellation, it reinforces the interpretation that these cells are reacting to something rather than transforming into something dangerous.

Additional Tests That Help Resolve Uncertain Cases

When cytology alone leaves doubt, several ancillary tests can push the answer in one direction or the other. One of the best-studied is UroVysion, a fluorescence-based test that looks for specific chromosomal abnormalities commonly found in bladder cancer cells. In a large evaluation of over 1,800 paired urine samples, UroVysion detected cancer in 48 out of 52 high-grade cases that cytology had classified as merely “atypical,” suggesting it works well as a follow-up test when cytology is equivocal.⁹ The same chromosomal approach has proven useful on tissue biopsies when pathologists struggle to tell reactive atypia from dysplasia under the microscope.¹⁰

Immunohistochemistry offers another avenue. When a biopsy is taken and the tissue looks ambiguous, pathologists can stain it with markers that behave very differently in cancerous versus reactive cells. CK20, a protein normally found only in the surface layer of healthy urothelium, lights up across the full thickness of the tissue in about three-quarters of carcinoma in situ cases but stays negative in reactive tissue. CD44, a surface molecule, shows the opposite pattern: it is positive in most reactive samples and rarely positive in carcinoma in situ. P53 and Ki67, markers associated with abnormal cell growth, are also far more commonly positive in cancerous tissue.¹¹

No single marker is perfect. One review noted that AMACR, another protein sometimes used alongside CK20, was highly specific but less sensitive, and p53 staining produced a meaningful rate of ambiguous results that were hard to interpret.¹² In practice, pathologists usually use a panel of several markers together rather than relying on any one of them.

What Usually Happens After a Reactive Finding

If your urine cytology says “reactive urothelial cells” and you have no symptoms or known risk factors for bladder cancer, the finding is generally treated as benign. Your doctor may recommend treating whatever caused the irritation, whether that is an infection or a stone, and repeating the test later to confirm the changes have resolved.

If the result says “atypical” rather than “reactive,” or if you have risk factors like a smoking history, visible blood in your urine, or a personal history of bladder cancer, the workup tends to be more aggressive. Cystoscopy, where a camera is inserted into the bladder, is the most direct way to look for tumors. Standard white-light cystoscopy catches most visible tumors, but flat lesions like carcinoma in situ can be invisible under white light. In one study of patients with suspicious or positive cytology but normal-appearing cystoscopy, switching to blue-light cystoscopy revealed bladder cancer in about 41% of cases. Nearly half of those cancers were visible only under blue light, and the majority turned out to be carcinoma in situ.¹³ That study underscores why abnormal cytology is taken seriously even when a standard scope looks clean.

For results firmly in the reactive category, cystoscopy is less urgent, but the decision depends on the full clinical picture. A young woman with a recent UTI and a reactive cytology finding is in a very different situation from a 70-year-old male smoker with the same lab report. Context drives the follow-up plan more than the cytology label alone.

Why the Report Can Still Feel Scary

Part of the problem is language. Urine cytology reports are written for doctors, not patients, and they use terms like “atypia,” “nuclear enlargement,” and “hyperchromasia” without much explanation. Seeing those words on a report you access through a patient portal, sometimes before your doctor has had a chance to discuss it, can trigger real anxiety. It helps to know that in this context, “reactive” is essentially the pathologist’s way of saying “irritated but not cancerous.”

The more genuinely worrying categories on a urine cytology report are “suspicious for high-grade urothelial carcinoma” and “positive for high-grade urothelial carcinoma.” Those labels carry much higher rates of confirmed cancer on follow-up. “Atypical urothelial cells” sits in the middle and warrants further investigation, but even that category contains many cases that turn out to be benign. “Reactive” is the lowest-concern abnormal finding.

Machine Learning and the Future of Urine Cytology

One reason urine cytology remains imperfect is that it depends heavily on human judgment. Two experienced pathologists can look at the same slide and disagree, especially for borderline cases. Researchers are now training machine-learning models to classify urine cells automatically. A recent study built models that could sort cells into normal, atypical, and suspicious categories with overall accuracy above 90%. The most powerful predictors for the algorithms were the same features pathologists have always relied on: the size of the nucleus and the nucleus-to-cytoplasm ratio.¹⁴

These tools are not ready to replace pathologists. The models performed well on normal and atypical cells but struggled with the suspicious category, correctly identifying suspicious cells less than a third of the time. That gap matters because suspicious cells are exactly the ones where accurate classification has the biggest clinical impact. Still, slide-level risk scores generated by averaging predictions across an entire specimen effectively separated negative, atypical, low-grade, and high-grade cases, suggesting the technology could eventually serve as a useful screening layer that flags the slides most likely to contain cancer for closer human review.